Adhera Therapeutics, Inc.
DelistedCIK 737207fmd_165EWN3KYKD9Q1WBT9RMTNW51DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2023, 54 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | – | – | – |
| Cost of revenue | – | – | – | – | – | 0 | 0 | – | – | – |
| Gross profit | – | – | – | – | – | (0) | (0) | – | – | – |
| Research and development | 1 | 1 | 0 | 0 | 1 | 0 | 0 | – | – | – |
| Selling, general and administrative | – | – | – | – | – | 10 | 10 | 2 | 1 | – |
| Total operating expenses | 2 | 4 | 1 | 1 | 6 | 16 | 11 | 2 | 1 | 2 |
| Operating income | (0) | (4) | (1) | (1) | (6) | (16) | (11) | (2) | (1) | (2) |
| Interest expense | – | – | – | – | – | – | 1 | – | – | – |
| Other non-operating income (expense) | (1) | (3) | 0 | (0) | (0) | (1) | – | (2) | (6) | (0) |
| Income before taxes | (2) | (6) | (1) | (1) | (6) | (17) | (12) | (4) | (6) | (2) |
| Income tax expense | (0) | – | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Net income from continuing operations | (2) | – | (1) | (1) | (6) | (17) | (12) | – | – | – |
| Net income | (2) | (6) | (1) | (1) | (6) | (17) | (12) | (4) | (6) | (2) |
| Net income to common shareholders | – | (12) | 3 | – | (6) | (18) | (13) | (5) | (8) | (3) |